OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT has a total of 37 patent applications. It decreased the IP activity by 54.0%. Its first patent ever was published in 2001. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals are THALAS GROUP INC, SHINKEI THERAPEUTICS LLC and SONG XUGANG.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 21 | |
#2 | EPO (European Patent Office) | 4 | |
#3 | WIPO (World Intellectual Property Organization) | 4 | |
#4 | Brazil | 2 | |
#5 | Argentina | 1 | |
#6 | Australia | 1 | |
#7 | Canada | 1 | |
#8 | Chile | 1 | |
#9 | Japan | 1 | |
#10 | Uruguay | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Franco Cristian R | 26 |
#2 | Meyer Glenn A | 23 |
#3 | Wright Claude E | 21 |
#4 | Fischbein Gustavo A | 21 |
#5 | Aguilar Alejandro A | 14 |
#6 | Faour Joaquina | 12 |
#7 | Pastini Ana C | 8 |
#8 | Bigatti Guido S | 7 |
#9 | Benedetti Hernan D | 7 |
#10 | Aikman Mark S | 5 |
Publication | Filing date | Title |
---|---|---|
US2019255005A1 | Controlled release dosage form | |
US2017354625A1 | Controlled release dosage form | |
US2017340570A1 | Controlled release dosage form with enhanced pharmacokinetics | |
US9707217B1 | Dose-dumping resistant controlled release dosage form | |
WO2016132217A1 | Method of improving gaba-b receptor agonist therapy | |
JP2012162533A | Multi-layered permeation device |